In one of the largest private rounds raised by an Italian biotech, Genespire Srl has closed a €46.6 million (US$51.88 million) series B, enabling it to lay the ground for a phase I/II clinical trial of its lead program, GENE-202, and to further develop its proprietary lentiviral vectors. The vectors are designed to be applicable to a range of liver-related metabolic disorders and, as its first indication, the company intends to treat methylmalonic acidemia, a serious genetic condition that results in impaired metabolism of certain amino acids and lipids.
Genespire Srl has closed a €46.6 million (~$52 million) series B financing to support its work developing off-the-shelf gene therapies based on immune shielded lentiviral vectors (ISLVs) for pediatric patients with genetic diseases.
Arrowhead Pharmaceuticals Inc. has filed for regulatory clearance to initiate a phase I/IIa trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed for obesity.
Breakthrough – or even better, revolutionary breakthrough – is perhaps the most overused term in drug development. But the discovery and development of GLP-1 receptor agonists (GLP-1RAs), which was honored with the 2024 Lasker-DeBakey Clinical Medical Research Award just last week, is one of the rare innovations that is deserving of the title.
An innovation that has kickstarted a revolution in the study and practice of health care is getting even more attention. Three scientists who pioneered the discovery and development of glucagon-like peptide-1 (GLP-1)-based obesity treatments have been named 2024 Lasker Award winners.
Scientists from the Cardiovascular Research Center at the University of Virginia School of Medicine and Astrazeneca plc have developed a new mouse model of cardiovascular disease associated with genetic variations of cholesterol metabolism. The animal allows in vivo studies of myocardial infarction, plaque rupture and stroke.
Huadong Medicine Co. Ltd. recently revealed data from in vitro and preclinical studies performed to evaluate the efficacy and pharmacokinetic, safety and tolerability profiles of a dual glucagon-like peptide 1 receptor (GLP-1R)/gastric inhibitory polypeptide receptor (GIPR) full agonist – HDM-1005.
The management of obesity and its associated comorbidities needs novel approaches for safety and efficacy. Researchers from Pep2tango Therapeutics Inc. are aiming to face this challenge by developing an approach that promotes superior weight loss through the loss of fat mass only, while preserving the muscle lean mass.
Nanovation Therapeutics Inc. has established a multiyear partnership with Novo Nordisk A/S to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership brings together Nanovation’s proprietary long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver, and Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation.
Previous research has demonstrated that patients treated with the second-generation antipsychotic olanzapine (OLA) have metabolic dysfunctions and insulin resistance. Researchers from Instituto de Investigaciones Biomedicas “Alberto Sols” and collaborators investigated the impact of intraperitoneal (i.p.) OLA treatment on peripheral insulin sensitivity as well as potential effects of inhibiting the protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling.
RSS
